The American Journal of Medicine
Volume 123, Issue 4 , Pages 358-366.e2 , April 2010

Systematic Review of the Symptom Burden, Quality of Life Impairment and Costs Associated with Peptic Ulcer Disease

  • Alan Barkun, MD, PhD

      Affiliations

    • Division of Gastroenterology, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Alan Barkun, MD, PhD, Division of Gastroenterology, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada
    • ,
  • Grigorios Leontiadis, MD, PhD

      Affiliations

    • Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada

References 

  1. Ehlin AG, Montgomery SM, Ekbom A, et al. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut. 2003;52:1117–1121
  2. Hein HO, Suadicani P, Gyntelberg F. Genetic markers for peptic ulcer (A study of 3387 men aged 54 to 74 years: the Copenhagen Male Study). Scand J Gastroenterol. 1997;32:16–21
  3. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? (Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000). Am J Gastroenterol. 2003;98:1494–1499
  4. Lau JY, Sung JJ, Metz DC, Howden CW. Systematic review of the epidemiology of complicated peptic ulcer: incidence, recurrence, risk factors and mortality. Gastroenterology. 2008;134(4 Suppl 1):A32
  5. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19
  6. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol. 2001;15:755–773
  7. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing. 1984;13:120–123
  8. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut. 1984;25:1089–1092
  9. Glynn MJ, Kane SP. Benign gastric ulceration in a health district: incidence and presentation. Postgrad Med J. 1985;61(718):695–700
  10. Talley NJ, Piper DW. Comparison of the clinical features and illness behaviour of patients presenting with dyspepsia of unknown cause (essential dyspepsia) and organic disease. Aust N Z J Med. 1986;16:352–359
  11. Sharma MP, Choudhari G. Nocturnal pain and duodenal ulcer. Br J Clin Pract. 1988;42:198–199
  12. Scapa E, Horowitz M, Waron M, Eshchar J. Duodenal ulcer in the elderly. J Clin Gastroenterol. 1989;11:502–506
  13. Johannessen T, Petersen H, Kleveland PM, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol. 1990;25:689–697
  14. Ahmed W, Qureshi H, Alam SE, Zuberi SJ. Pattern of duodenal ulcer in Karachi. J Pak Med Assoc. 1990;40:212–215
  15. Ahmed WU, Qureshi H, Alam SE, Zuberi SJ. Site of duodenal ulcer and its influence on the mode of presentation and prognosis. J Pak Med Assoc. 1990;40:238–239
  16. Brazer SR, Tyor MP, Pancotto FS, et al. Studies of gastric ulcer disease by community-based gastroenterologists. Am J Gastroenterol. 1990;85:824–828
  17. Goenka MK, Kochhar R, Ghosh P, Mehta SK. Changing pattern of peptic ulcer in India (An endoscopic study of 1,188 ulcer patients). J Clin Gastroenterol. 1991;13:575–579
  18. Johnsen R, Bernersen B, Straume B, et al. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ. 1991;302(6779):749–752
  19. Grebenev AL, Sheptulin AA. Diagnostic value of some subjective and objective symptoms of gastric ulcer. Mater Med Pol. 1992;24:82–83
  20. Ahmed W, Qureshi H, Alam SE, Zuberi SJ. Gastric ulcer in Karachi. J Pak Med Assoc. 1992;42:207–210
  21. Chunlertrith K, Sukeepaisarnjaroen W, Mairiang E, et al. The study of discriminant values of dyspeptic symptoms for identifying the etiology of dyspepsia. J Med Assoc Thai. 1992;75:341–349
  22. Schubert TT, Bologna SD, Nensey Y, et al. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med. 1993;94:413–418
  23. Mansi C, Mela GS, Savarino V, et al. Open access endoscopy: a large-scale analysis of its use in dyspeptic patients. J Clin Gastroenterol. 1993;16:149–153discussion 153-154
  24. Numans ME, Van der Graaf Y, de Wit NJ, et al. How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy. Fam Pract. 1994;11:382–388
  25. Ayuo PO, Nugent CE. Dyspepsia: preliminary experience with upper gastrointestinal fibreoptic endoscopy in Eldoret. East Afr Med J. 1994;71:261–263
  26. Sharma BC, Pal LS, Rana S. Aetiology and dynamics of dyspepsia in Shimla: a study of 500 patients. Trop Gastroenterol. 1994;15:213–218
  27. Kang JY, Ho KY, Yeoh KG, Guan R. Chronic upper abdominal pain due to duodenal ulcer and other structural and functional causes: its localization and nocturnal occurrence. J Gastroenterol Hepatol. 1996;11:515–519
  28. Werdmuller BF, van der Putten AB, Loffeld RJ. The clinical presentation of peptic ulcer disease. Neth J Med. 1997;50:115–119
  29. Ahmed ME, al-Knawy BA, al-Wabel AH, Foli AK. Duodenal ulcer and Helicobacter pylori infection at high altitude: experience from southern Saudi Arabia. Can J Gastroenterol. 1997;11:313–316
  30. Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology. 1997;43:283–288
  31. Abahussain EA, Hasan FA, Nicholls PJ. Dyspepsia and Helicobacter pylori infection: analysis of 200 Kuwaiti patients referred for endoscopy. Ann Saudi Med. 1998;18:502–505
  32. Seinela L, Ahvenainen J. Peptic ulcer in the very old patients. Gerontology. 2000;46:271–275
  33. Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol. 2001;96:380–384
  34. Kolk H. Evaluation of symptom presentation in dyspeptic patients referred for upper gastrointestinal endoscopy in Estonia. Croat Med J. 2004;45:592–598
  35. Bancu L, Georgescu D, Ureche C, Bancu S. A prospective, randomized study on duodenal ulcer. Ann Fundeni Hosp. 2004;9(1-2):10–12
  36. Karima TM, Bukhari SZ, Ghais MA, et al. Prevalence of Helicobacter pylori infection in patients with peptic ulcer diseases. Saudi Med J. 2006;27:621–626
  37. Dimenäs E, Glise H, Hallerbäck B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–1052
  38. Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129–134
  39. Dimenäs E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl. 1996;221:8–13
  40. Mokrowiecka A, Jurek K, Pinkowski D, Malecka-Panas E. The comparison of health-related quality of life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Adv Med Sci. 2006;51:142–147
  41. Martin C, Marquis P, Bonfils S. A ‘quality of life questionnaire’ adapted to duodenal ulcer therapeutic trials. Scand J Gastroenterol Suppl. 1994;29(206):40–43
  42. Dimenäs E, Glise H, Hallerbäck B, et al. Quality of life in patients with upper gastrointestinal symptoms (An improved evaluation of treatment regimens?). Scand J Gastroenterol. 1993;28:681–687
  43. Glise H. Quality of life assessments in patients with peptic ulcer during treatment and follow-up. Scand J Gastroenterol Suppl. 1993;199:34–35
  44. Hallerback B. Assessment of quality of life among patients with suspected duodenal ulcer. Scand J Gastroenterol Suppl. 1993;199:32–33
  45. Glise H, Hallerback B, Johansson B. Quality of life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl. 1995;208:133–135
  46. Hallerback B, Glise H, Svedlund J, et al. Quality of life in duodenal ulcer treatment: a comparison of omeprazole and ranitidine in acute and intermittent treatment. Psychol Health Med. 1998;3:417–427
  47. Wilhelmsen I. Quality of life and Helicobacter pylori eradication. Scand J Gastroenterol Suppl. 1996;221:18–20
  48. Wilhelmsen I, Haug TT, Ursin H, Berstad A. Discriminant analysis of factors distinguishing patients with functional dyspepsia from patients with duodenal ulcer: significance of somatization. Dig Dis Sci. 1995;40:1105–1111
  49. Rampal P, Martin C, Marquis P, et al. A quality of life study in five hundred and eighty-one duodenal ulcer patients (Maintenance versus intermittent treatment with nizatidine). Scand J Gastroenterol Suppl. 1994;206:44–51
  50. Rampal P, Ruszniewski P, Boureau F, et al. Pain and quality of life in patients with acute duodenal ulcer treated with ranitidine. Aliment Pharmacol Ther. 1995;9:433–439
  51. Crawley J, Frank L, Joshua-Gotlib S, et al. Measuring change in quality of life in response to Helicobacter pylori eradication in peptic ulcer disease: the QOLRAD. Dig Dis Sci. 2001;46:571–580
  52. Fujiwara Y, Higuchi K, Arafa UA, et al. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology. 2002;49(47):1298–1302
  53. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51):1–164
  54. Groeneveld PW, Lieu TA, Fendrick AM, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol. 2001;96:338–347
  55. Higashi T, Sakurai H, Satoh T, Toyama T. Absenteeism of shift and day workers with special reference to peptic ulcer. Asia Pac J Public Health. 1988;2:112–119
  56. Bloom BS, Gessner U. Long-term technology assessment (Mortality, hospitalization, and work loss due to peptic ulcer and gastritis/duodenitis in the Federal Republic of Germany). Int J Technol Assess Health Care. 1989;5:215–226
  57. Bloom BS, Fendrick AM, Ramsey SD. Changes in peptic ulcer and gastritis/duodenitis in Great Britain, 1970-1985. J Clin Gastroenterol. 1990;12:100–108
  58. Joish VN, Donaldson G, Stockdale W, et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database database. Curr Med Res Opin. 2005;21:535–544
  59. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997;92:614–620
  60. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol. 2000;95:788–792
  61. Ruszniewski P. Pharmaco-economic considerations in the long-term management of peptic ulcer disease. Aliment Pharmacol Ther Suppl. 1993;7:41–48
  62. The World Bank. World Development Indicators 2008. http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:22151356∾pagePK:64133150∾piPK:64133175∾theSitePK:239419,00.html
  63. US Census Bureau. Historical National Population Estimates: July 1, 1900-July 1 1995. Washington DC: Government Printing Office; 2000;
  64. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511
  65. Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol. 2001;36:775–779
  66. Statistics Sweden. Demographic Analysis (Demography). Stockholm: Statistics Sweden; 2008;
  67. Xu W, Hood HM, Burgess PA. The description of outcomes in Medicare patients hospitalized with peptic ulcer disease. Am J Gastroenterol. 2000;95:264–270
  68. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med. 1997;103:520–528
  69. Marshall JK, Collins SM, Gafni A. Prediction of resource utilization and case cost for acute nonvariceal upper gastrointestinal hemorrhage at a Canadian community hospital. Am J Gastroenterol. 1999;94:1841–1846
  70. Marshall JK, Collins SM, Gafni A. Demographic predictors of resource utilization for bleeding peptic ulcer disease: the Ontario GI Bleed Study. J Clin Gastroenterol. 1999;29:165–170
  71. Kong SX, Hatoum HT, Zhao SZ, et al. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care. 1998;4:399–409
  72. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics. 2002;20:347–355
  73. de Leest H, van Dieten H, van Tulder M, et al. Costs of treating bleeding and perforated peptic ulcers in the Netherlands. J Rheumatol. 2004;31:788–791
  74. Erstad BL, Camamo JM, Miller MJ, et al. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med. 1997;25:1678–1684
  75. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol. 2000;95:788–792
  76. Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol. 2001;36:775–779
  77. Sung J, Lau JYW, Ching JYL, et al. Early reintroduction of aspirin with proton pump inhibitor after endoscopic hemostasis for peptic ulcer bleeding: final results of a double blinded randomized study. Gut. 2007;56(Suppl 3):A27
  78. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890–2907
  79. Targownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol Ther. 2008;28:88–96

 Funding: Writing support was provided by Dr. Catherine Henderson (Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, UK), funded by AstraZeneca R&D Mölndal, Sweden.

 Conflict of Interest: Dr. Alan Barkun is a consultant for AstraZeneca Inc. Dr. Grigorios Leontiadis has received speaker honoraria from AstraZeneca, Sanofi-Aventis, GlaxoSmithKline, and Janssen-Cilag.

 Authorship: This work is original, and the authors meet the criteria for authorship and accept responsibility for the scientific content of the manuscript.

PII: S0002-9343(09)01068-7

doi: 10.1016/j.amjmed.2009.09.031

The American Journal of Medicine
Volume 123, Issue 4 , Pages 358-366.e2 , April 2010

Article Tools

* Image Usage & Resolution